Research Analysts Issue Forecasts for Genmab A/S Q4 Earnings

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at William Blair raised their Q4 2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research report issued on Monday, October 20th. William Blair analyst M. Phipps now anticipates that the company will earn $0.44 per share for the quarter, up from their previous forecast of $0.42. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS.

Several other analysts also recently weighed in on the company. Zacks Research upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Truist Financial boosted their price target on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Tuesday, September 23rd. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Genmab A/S in a report on Wednesday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Stock Performance

Genmab A/S stock opened at $30.13 on Tuesday. The business’s 50-day simple moving average is $28.30 and its two-hundred day simple moving average is $23.52. The company has a market cap of $19.35 billion, a PE ratio of 15.14, a PEG ratio of 1.71 and a beta of 0.98. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $33.65.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently bought and sold shares of the business. Osaic Holdings Inc. raised its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. CWM LLC raised its holdings in shares of Genmab A/S by 28.3% during the third quarter. CWM LLC now owns 2,306 shares of the company’s stock valued at $71,000 after acquiring an additional 509 shares during the last quarter. Captrust Financial Advisors raised its holdings in shares of Genmab A/S by 2.4% during the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock valued at $464,000 after acquiring an additional 526 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Genmab A/S by 3.2% during the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock valued at $332,000 after acquiring an additional 532 shares during the last quarter. Finally, Yousif Capital Management LLC raised its holdings in shares of Genmab A/S by 7.8% during the second quarter. Yousif Capital Management LLC now owns 10,943 shares of the company’s stock valued at $226,000 after acquiring an additional 790 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.